Nuclear Receptor Signaling is indexed in MEDLINE and full text articles are available on PubMed Central. Browse a list of previously published Nuclear Receptor Signaling articles on PubMed and PubMed Central.
An introductory article processing charge (APC) of 625 USD, discounted from the full rate of 1,250 USD, is available for a limited time. *The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.
Submit your manuscript today at https://mc04.manuscriptcentral.com/nrsignaling.
Please direct any enquiries to email@example.com
The scope of this journal is to act as a unique, pan-disciplinary home for innovative and insightful research in nuclear receptor signaling.
The Editors-in-Chief welcome submissions representing the broad range of disciplines in this field, including cell biology, biochemistry, physiology, chemistry, pharmacology and informatics, as well as clinical and translational studies.
|Neil J. McKenna, PhD||Baylor College of Medicine, USA|
|Trevor Archer||National Institute of Health, USA|
|Johan Auwerx||Ecole Polytechnique Federale de Lausanne, Switzerland|
|Miguel Beato||Centre de Regulació Genòmica, Spain|
|Bruce Blumberg||University of California Irvine, USA|
|Myles Brown||Dana-Farber Cancer Institute, Boston, MA, USA|
|Jason Carroll||University of Cambridge, Cambridge, UK|
|Pierre Chambon||Institut de Génétique et de Biologie Moléculaire et Cellulaire, France|
|Christine Clark||The University of Sydney, Australia|
|Orla Conneely||Baylor College of Medicine, USA|
|Austin Cooney||Dell Medical School, University of Texas, Austin, USA|
|Vincent Giguere||McGill University, Canada|
|Christopher Glass||University of California at San Diego, USA|
|Geoffrey Greene||Ben May Department for Cancer Research, The University of Chicago|
|Hinrich Gronemeyer||Institut de Génétique et de Biologie Moléculaire et Cellulaire, France|
|Jan-Ake Gustafsson||University of Houston, USA|
|Benita Katzenellenbogen||University of Illinois, USA|
|Dan Kelly||Penn Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, USA|
|Steve Kliewer||University of Texas Southwestern, USA|
|Karen Knudsen||Thomas Jefferson University, USA|
|Ken Korach||National Institute of Health, USA|
|Anastasia Kralli||Scripps Institute, USA|
|W. Lee Kraus||University of Texas Southwestern, USA|
|Vincent Laudet||Institut de Génomique Fonctionnelle de Lyon, France|
|Mitchell Lazar||University of Pennsylvania, USA|
|Adriana Maggi||University of Milan, Italy|
|David Moore||Baylor College of Medicine, USA|
|Dino Moras||Institut de Génétique et de Biologie Moléculaire et Cellulaire, France|
|George Muscat||University of Queensland, Australia|
|Malcolm Parker||Imperial College London, UK|
|Didier Picard||University of Geneva, Switzerland|
|Fraydoon Rastinejad||Sanford-Burnham Medical Research Institute, USA|
|Inez Rogatsky||Hospital for Special Surgery, USA|
|Michael G. Rosenfeld||University of California at San Diego, USA|
|John Schwabe||University of Leicester, UK|
|Bruce Spiegelman||Harvard Medical School , USA|
|Carl Thummel||The University of Utah, USA|
|Eckard Treuter||Karolinska Institute, Sweden|
|Ming-Jer Tsai||Baylor College of Medicine, USA|
|Sophia Tsai||Baylor College of Medicine, USA|
|Nancy Weigel||Baylor College of Medicine, USA|
|Eric Xu||Van Andel Research Institute, USA|
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Nuclear Receptor Signaling will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Please Read the Manuscript Submission Guidelines below before submitting your manuscript here:
- Open Access
- Article processing charge (APC)
- What do we publish?
3.1 Aims & scope
3.2 Article types
3.3 Writing your paper
3.3.1 Making your article discoverable
- Editorial policies
4.1 Peer Review Policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
4.9 Dataset deposition
4.10 NIH Rigor and Transparency Guidelines
- Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement
- Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplemental material
6.4 Reference style
6.5 English language editing services
- Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
- On acceptance and publication
8.1 SAGE Production
8.2 Continuous publication
8.3 Promoting your article
- Further information
Nuclear Receptor Signaling is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license.
An introductory article processing charge (APC) of 625 USD, discounted from the full rate of 1,250 USD, is available for a limited time.
*If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.
Before submitting your manuscript to Nuclear Receptor Signaling, please ensure you have read the Aims & Scope.
- Original manuscript: Provides the results of original laboratory and/or clinical research. Components indicated by a checkmark below should appear in the order they are presented here (ie. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures). Word Limit: 2500 words (exceptions allowed under special circumstances)
- Review: Manuscript that provides a review of previously published literature. Components indicated by a checkmark below should appear in the order they are presented here (ie. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures) Word limit: 3000 words
- Clinical Trial
- Letters to the Editor: Letters should be a brief communication commenting on an article recently published in the Journal. Letters to the editor will be reviewed by the Editor(s) and peer-reviewed. Letters to the Editor are limited to 500 words and 5 references. Because letters to the editor are indexed and can be cited, key words are also required. Letters to the Editor will be published exclusively online, with exceptions per the Editor.
- Case Reports: Nuclear Receptor Signaling will review case reports that are truly unique and have an exceptional teaching value.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online
The journal’s policy is to have manuscripts reviewed by two expert reviewers. Nuclear Receptor Signaling utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor-in-Chief who then makes the final decision.
FOR JOURNALS USING RECOMMENDED/OPPOSED REVIEWERS
As part of the submission process you will be asked to provide the names of [X #] peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
• The reviewer should have no prior knowledge of your submission
• The reviewer should not have recently collaborated with any of the authors
• Reviewer nominees from the same institution as any of the authors are not permitted
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).
Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor / Board member will have no involvement in the decision-making process.
Nuclear Receptor Signaling is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for Nuclear Receptor Signaling can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
(i) Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
(ii) Drafted the article or revised it critically for important intellectual content,
(iii) Approved the version to be published,
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Nuclear Receptor Signaling requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Nuclear Receptor Signaling to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
Nuclear Receptor Signaling conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
At SAGE we are committed to facilitating openness, transparency and reproducibility of research. Nuclear Receptor Signaling requires authors to share their research data in a suitable public repository as a condition of publication. This is subject to ethical considerations and in such cases the journal editor may grant an exception and authors should contact the Editorial Office. Authors are also required to include a data accessibility statement in their manuscript file and to follow data citation principles. For more information please visit the SAGE Author Gateway, which includes information about SAGE’s partnership with the data repository Figshare.
Nuclear Receptor Signaling is pleased to support of the NIH Rigor and Transparency guidelines. Part of these guidelines are to clearly identify all “Key Biological Resources”, which include antibodies, cell lines, and model organisms used in the study and the editors strongly encourage you to add RRIDs to your methods section for all key resources including software tools which have been shown to be key sources of variability in experiments. To help our authors transparently cite resources there is a single web site where tools can be found and a “cite this” button next to each resource that contains proper citation text that should be included in the methods section of your manuscript. Several examples of properly formatted methods text can be found below:
• Antibodies: "Sections were stained with a NeuN antibody (Millipore Cat# MAB377, Lot#307 RRID:AB_2298772)."
• Cell Lines: "Subjects include the following cell line obtained from the CLS cell repository, CLS Cat# 300384/p699_HeLa_S3, RRID:CVCL_0058.”
• Organisms: "Subjects in this study were Tlx3 transgenic mice obtained from MMRRC (RRID:MMRRC_036547-UCD)"
• Software tools: "...terminals were mapped with a computer-assisted mapping program (Neurolucida, v10, RRID:SCR_001775)."
Note to authors, searching the website by catalog or stock number is usually most effective in quickly retrieving the correct resource.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway
Nuclear Receptor Signaling and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Nuclear Receptor Signaling publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Preparing your Manuscript page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Artwork Guidelines.
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For information on data sharing and where to upload data, please visit SAGE's Data Sharing Policies.
Nuclear Receptor Signaling adheres to the AMA (American Medical Association) reference style. Please review the guidelines on AMA style to ensure your manuscript conforms to this reference style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Nuclear Receptor Signaling is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit the journal’s submission site to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed on the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognized.
We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Nuclear Receptor Signaling editorial office as follows:
Kiley Allen, Associate Publishing Editor Kiley.firstname.lastname@example.org